GLP-1s & incretins · Metabolic & endocrine
Lixisenatide
A once-daily GLP-1 receptor agonist for glycaemic control in type 2 diabetes — shorter-acting than the weekly agents that dominate headlines.
- How settled this rating is:
- high confidence in the current evidence rating
- Routes studied:
- Subcutaneous injection
- Also known as:
- Adlyxin, Lyxumia
- Last reviewed:
- 2026-08-23
Jump to section
Evidence passport
Lixisenatide
A one-screen evidence identity for this compound. These fields describe research maturity, confidence and legal status. They are not a safety guarantee, efficacy percentage or recommendation.
- Evidence level
- L5Repeated human trials
- Confidence
- High confidence in rating
- Regulatory status
- Approved medicine (jurisdiction-specific) · See jurisdiction details
- Development status
- Approved
Evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
The 0-100 values rate the strength and maturity of evidence, not how effective or safe the compound is.
- Evidence base
- Includes human studies
- Furthest established stage
- Approved
- Human research maturity
- Established GLP-1 medicine
- Source curation
- Sources fully curated
Routes recorded
Overview
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
How far human research has progressed: Established GLP-1 medicine
Routes & formulations
Studied / approved routes
The approved product is a once-daily subcutaneous injection; schedules differ across the GLP-1 class.
Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.
Peptide lifecycle
Discovery
Preclinical
Phase I
Phase II
Phase III
Approved
What it is
An exendin-4-derived GLP-1-receptor agonist peptide with a shorter duration of action than weekly GLP-1 medicines.
What people claim
- Improves glycaemic control in type 2 diabetes
What the evidence actually says
The trial programme supporting approval included a cardiovascular-outcomes trial (ELIXA) that established cardiovascular safety in a high-risk population without showing the event reduction seen with some other class members — an honest reminder that GLP-1s are not interchangeable.
Related evidence
Useful next reads based on this compound — not recommendations.
- Related compound
Exenatide evidence profile
The first GLP-1 receptor agonist — born from Gila-monster venom peptide biology — with formulations ranging from twice-daily to weekly injection.
- Compare
Compare Lixisenatide vs Exenatide evidence
Same questions, same fields, side by side — including how much human evidence exists.
- Checked claim
Claim review: “All GLP-1 peptide drugs are weekly injections.”
A closely related claim we have graded, from GLP-1s & incretins.
- Context
GLP-1 Centre
How the incretin medicines compare on trial evidence and where they are actually licensed.
Human evidence
- Pivotal randomised glycaemic-control trials.
- ELIXA cardiovascular-outcomes trial in type 2 diabetes after acute coronary syndrome.
Preclinical evidence
- GLP-1-receptor pharmacology.
Animal and cell findings are Level 1–2 evidence.
Mechanism and pathways
- GLP-1-receptor agonism: glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying.
Safety and unknowns
- Labelled class effects include gastrointestinal symptoms and pancreatitis warnings.
- Combination with insulin secretagogues raises hypoglycaemia risk, as labelled.
Cancer relevance
This section covers questions raised by how the compound works in the body, plus anything regulators and trial teams keep an eye on. It is not a statement that this compound causes cancer — for most compounds here, no human data exist in either direction.
No concern identified
Regulatory status
Regulatory decisions apply to specific jurisdictions, products, formulations and indications. An approval elsewhere is not automatically an approval in your country.
Named regulators: FDA (US)
FDA-approved (Adlyxin) as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes; also marketed in some regions as Lyxumia.
Evidence grade
Substantial, consistent controlled human evidence supporting a specified outcome, preferably independently replicated. Approval is reported separately.
What would change our rating?
- Not applicable at this evidence tier.
References and sources
Source transparency
A provenance snapshot of this profile. Counts show what kinds of sources are cited, not how much scientific weight each source deserves.
- Last editorial review
- 2026-08-23
- Recently reviewed · 54 days ago
- Linked curated sources
- 1
- Sources still pending
- 0
- External specialist reviews
- 0
- None recorded for this profile
Review provenance
Registry editorial review: Colin Jackson-White, creator and editor, who is not a doctor or clinician. External specialist review is credited only when a named reviewer has completed a review of this exact profile.
Literature-discovery and AI tools may help locate or challenge candidate evidence, but they are not counted as evidence sources here. Registry judgements are tied to the underlying papers, trial records, regulator documents and official study records.
- Regulatory / labelFDA label: Adlyxin (lixisenatide) injection
Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.
Evidence change history
These entries record changes to our assessment of the published evidence — not changes to the compound itself.
No recorded changes yet. Baseline position set on 2026-08-23.